Caffeine in Parkinson's disease: A pilot open‐label, dose‐escalation study
Identifieur interne : 000379 ( Main/Exploration ); précédent : 000378; suivant : 000380Caffeine in Parkinson's disease: A pilot open‐label, dose‐escalation study
Auteurs : Robert D. Altman [Canada] ; Anthony E. Lang [Canada] ; Ronald B. Postuma [Canada]Source :
- Movement Disorders [ 0885-3185 ] ; 2011-11.
English descriptors
Abstract
Introduction:: Epidemiologic studies consistently find an inverse association between caffeine use and PD. Numerous explanations exist, but are difficult to evaluate as caffeine's symptomatic effect and tolerability in PD are unknown. Patients and Methods:: We designed an open‐label, 6‐week dose‐escalation study of caffeine to establish dose tolerability and evaluate potential motor/nonmotor benefits. Caffeine was started at 200 mg daily and was increased to a maximum of 1,000 mg. Results:: Of 25 subjects, 20 tolerated 200 mg, 17 tolerated 400 mg, 7 tolerated 800 mg, and 3 tolerated 1,000 mg. The most common adverse events were gastrointestinal discomfort, anxiety, and worsening/emerging tremor. At 400 mg daily, we found potential improvements in motor manifestations and somnolence (UPDRS III: −4.5 ± 4.6, P = 0.003; Epworth: −2.0 ± 3.0, P = 0.015). Conclusion:: Maximum dose tolerability for caffeine in PD appears to be 100 to 200 mg BID. We found pilot preliminary evidence that caffeine may improve some motor and nonmotor aspects of PD, which must be confirmed in longer term, placebo‐controlled, clinical trials. © 2011 Movement Disorder Society
Url:
DOI: 10.1002/mds.23873
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Caffeine in Parkinson's disease: A pilot open‐label, dose‐escalation study</title><author><name sortKey="Altman, Robert D" sort="Altman, Robert D" uniqKey="Altman R" first="Robert D." last="Altman">Robert D. Altman</name></author><author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name></author><author><name sortKey="Postuma, Ronald B" sort="Postuma, Ronald B" uniqKey="Postuma R" first="Ronald B." last="Postuma">Ronald B. Postuma</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:666335AD5F4D71A3CA4FC44E73116C703D26661C</idno><date when="2011" year="2011">2011</date><idno type="doi">10.1002/mds.23873</idno><idno type="url">https://api.istex.fr/document/666335AD5F4D71A3CA4FC44E73116C703D26661C/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">001511</idno><idno type="wicri:Area/Main/Curation">001287</idno><idno type="wicri:Area/Main/Exploration">000379</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Caffeine in Parkinson's disease: A pilot open‐label, dose‐escalation study</title><author><name sortKey="Altman, Robert D" sort="Altman, Robert D" uniqKey="Altman R" first="Robert D." last="Altman">Robert D. Altman</name><affiliation wicri:level="4"><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Neurology, McGill University, Montreal General Hospital, Montreal, Quebec</wicri:regionArea><orgName type="university">Université McGill</orgName><placeName><settlement type="city">Montréal</settlement><region type="state">Québec</region></placeName></affiliation></author><author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Morton and Gloria Shulman Movement Disorders center, Toronto Western Hospital, Toronto, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Postuma, Ronald B" sort="Postuma, Ronald B" uniqKey="Postuma R" first="Ronald B." last="Postuma">Ronald B. Postuma</name><affiliation wicri:level="4"><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Neurology, McGill University, Montreal General Hospital, Montreal, Quebec</wicri:regionArea><orgName type="university">Université McGill</orgName><placeName><settlement type="city">Montréal</settlement><region type="state">Québec</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2011-11">2011-11</date><biblScope unit="volume">26</biblScope><biblScope unit="issue">13</biblScope><biblScope unit="page" from="2427">2427</biblScope><biblScope unit="page" to="2431">2431</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">666335AD5F4D71A3CA4FC44E73116C703D26661C</idno><idno type="DOI">10.1002/mds.23873</idno><idno type="ArticleID">MDS23873</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term><term>caffeine</term><term>clinical trials</term><term>neuroprotection</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Introduction:: Epidemiologic studies consistently find an inverse association between caffeine use and PD. Numerous explanations exist, but are difficult to evaluate as caffeine's symptomatic effect and tolerability in PD are unknown. Patients and Methods:: We designed an open‐label, 6‐week dose‐escalation study of caffeine to establish dose tolerability and evaluate potential motor/nonmotor benefits. Caffeine was started at 200 mg daily and was increased to a maximum of 1,000 mg. Results:: Of 25 subjects, 20 tolerated 200 mg, 17 tolerated 400 mg, 7 tolerated 800 mg, and 3 tolerated 1,000 mg. The most common adverse events were gastrointestinal discomfort, anxiety, and worsening/emerging tremor. At 400 mg daily, we found potential improvements in motor manifestations and somnolence (UPDRS III: −4.5 ± 4.6, P = 0.003; Epworth: −2.0 ± 3.0, P = 0.015). Conclusion:: Maximum dose tolerability for caffeine in PD appears to be 100 to 200 mg BID. We found pilot preliminary evidence that caffeine may improve some motor and nonmotor aspects of PD, which must be confirmed in longer term, placebo‐controlled, clinical trials. © 2011 Movement Disorder Society</div></front></TEI><affiliations><list><country><li>Canada</li></country><region><li>Québec</li></region><settlement><li>Montréal</li></settlement><orgName><li>Université McGill</li></orgName></list><tree><country name="Canada"><region name="Québec"><name sortKey="Altman, Robert D" sort="Altman, Robert D" uniqKey="Altman R" first="Robert D." last="Altman">Robert D. Altman</name></region><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name><name sortKey="Postuma, Ronald B" sort="Postuma, Ronald B" uniqKey="Postuma R" first="Ronald B." last="Postuma">Ronald B. Postuma</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000379 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000379 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:666335AD5F4D71A3CA4FC44E73116C703D26661C
|texte= Caffeine in Parkinson's disease: A pilot open‐label, dose‐escalation study
}}
| This area was generated with Dilib version V0.6.23. |  |